• / Free eNewsletters & Magazine
  • / My Account
Home>Authors>Damien Conover

Damien Conover

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  5. Research
  1. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover .

  2. Ultimate Stock-Pickers’ Top 10 High-Conviction and New-Money Purchases

    Top managers were finding new places to put money to work and adding to existing high-conviction ideas in the first quarter.

  3. Market Undervalues Merck’s Pipeline

    New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover .

  4. Friday Five: Banks Start Earnings Season Without a Bang

    Plus, strong results push Netflix shares further out of reach this week, while Google stock gets more interesting as European regulators make a move.

  5. J&J Faces Headwinds in 2015

    The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .

  6. Prescribe to Pharma for Emerging-Markets Growth

    Many developed-country health-care firms have deep roots in emerging markets and can be a good way to gain exposure, says Morningstar's Damien Conover .

  7. J&J's Strong 2Q Led by Pharmaceuticals

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  8. Johnson & Johnson's Pharma Group Leading the Way

    The firm's consumer and medical-device group are lagging, but strong results from the pharmaceuticals side should drive earnings throughout this year and into 2015, says Morningstar's Damien Conover .

  9. Pfizer-Astra Deal Will Get Done

    Cost-cutting, tax opportunities, and oncology synergies are motivating factors for Pfizer, and the firms will likely agree to merge, says Morningstar's Damien Conover .

  10. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.